Karyopharm Therapeutics, Inc. (KPTI)
9.11
+0.42
(+4.83%)
USD |
NASDAQ |
Jun 10, 16:00
9.11
0.00 (0.00%)
Pre-Market: 08:14
Karyopharm Therapeutics Enterprise Value : 345.40M for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 345.40M |
| June 09, 2026 | 335.93M |
| June 08, 2026 | 331.65M |
| June 05, 2026 | 344.72M |
| June 04, 2026 | 344.50M |
| June 03, 2026 | 342.92M |
| June 02, 2026 | 348.11M |
| June 01, 2026 | 361.41M |
| May 29, 2026 | 345.17M |
| May 28, 2026 | 345.40M |
| May 27, 2026 | 343.54M |
| May 26, 2026 | 343.31M |
| May 22, 2026 | 324.95M |
| May 21, 2026 | 322.69M |
| May 20, 2026 | 320.87M |
| May 19, 2026 | 309.32M |
| May 18, 2026 | 301.84M |
| May 15, 2026 | 313.85M |
| May 14, 2026 | 341.72M |
| May 13, 2026 | 340.59M |
| May 12, 2026 | 342.06M |
| May 11, 2026 | 339.68M |
| May 08, 2026 | 335.83M |
| May 07, 2026 | 340.59M |
| May 06, 2026 | 343.44M |
| Date | Value |
|---|---|
| May 05, 2026 | 352.23M |
| May 04, 2026 | 349.75M |
| May 01, 2026 | 337.80M |
| April 30, 2026 | 327.43M |
| April 29, 2026 | 329.45M |
| April 28, 2026 | 333.90M |
| April 27, 2026 | 335.26M |
| April 24, 2026 | 335.26M |
| April 23, 2026 | 337.28M |
| April 22, 2026 | 355.32M |
| April 21, 2026 | 346.75M |
| April 20, 2026 | 341.57M |
| April 17, 2026 | 334.13M |
| April 16, 2026 | 335.26M |
| April 15, 2026 | 333.00M |
| April 14, 2026 | 330.52M |
| April 13, 2026 | 326.69M |
| April 10, 2026 | 320.38M |
| April 09, 2026 | 323.98M |
| April 08, 2026 | 303.47M |
| April 07, 2026 | 302.57M |
| April 06, 2026 | 282.50M |
| April 02, 2026 | 272.81M |
| April 01, 2026 | 271.23M |
| March 31, 2026 | 265.59M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gilead Sciences, Inc. | 163.15B |
| Catalyst Pharmaceuticals, Inc. | 3.076B |
| Incyte Corp. | 17.10B |
| Inovio Pharmaceuticals, Inc. | 47.07M |
| Cellectar Biosciences, Inc. | 4.667M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -22.39M |
| Revenue (Quarterly) | 35.07M |
| Total Expenses (Quarterly) | 57.46M |
| EPS Diluted (Quarterly) | -1.236 |
| Gross Profit Margin (Quarterly) | 96.13% |
| Profit Margin (Quarterly) | -63.86% |
| Earnings Yield | -165.6% |
| Normalized Earnings Yield | -138.85 |